anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open-label, single arm pilot study in participants prescribed low or medium dose ICS/LABA inhaled therapy and poorly controlled asthma to quantify hyperpolarized 129Xe MRI VDP before and after six weeks of therapy with FF/UMEC/VI 200/62.5/25 ug QD. Male and females between 18 and 70 years of age will provide written informed consent to five visits including screening (Visit 1 week -2), baseline (Visit 2 week 0), mid-study Visit 3 in week 3, study end (Visit 4, week +6) and safety follow-up (Visit 5 week +8). The general study procedures are the same for Visit 1/Day -14, Visit 2/Day 0 and Visit 4/Day 42. Visit 3/Day 21 is an optional clinic visit or phone call. Visit 5 is a phone call check-in for adverse events.

For Visits 1, 2 and 4, participants are to withhold their medication as previously described. Vital signs will be recorded at the beginning of the visit. FeNO, spirometry, plethysmography, FOT, MBNW and 129Xe MRI will be performed pre-bronchodilator. FeNO will be performed before all other pulmonary function testing. Following 129Xe MRI, all participants will inhale 4 puffs (100mcg each) of a bronchodilator and quietly rest for 15 minutes. After 15 minutes, participants will undergo post-bronchodilator 129Xe MRI, and once MRI is complete, participants will undergo post-bronchodilator spirometry, plethysmography, FOT and MBNW. SGRQ, ACQ-6 and AQLQ will be administered after post-bronchodilator assessments are completed. For Visit 3, participants who choose to attend an in-person visit are to withhold their medication as described and the process for Visits 1, 2 and 4 will be followed. Participants who choose a phone call Visit 3 will be asked a series of questions regarding their breathing, asthma control and general health and they will complete the SGRQ, ACQ and AQLQ. For all participants, Visit 5 will entail a phone call check-in for adverse events. CT will be acquired at Visit 2, whilst MRI will be acquired on Visits 2, 4 and for those who prefer an in person visit, on Visit 3.
Aerosolized medication is used widely to patients with respiratory illness and admitted in the intensive care unit, and includes bronchodilators, steroids, mucolytics, and antibiotics. Aerosol delivery through a ventilator is influenced by numerous factors from ventilator-related, circuit-related to device-related factors. Aerosolized drug delivery through a ventilator system was studied on bench model with albuterol, yet the results were often overestimated. Only few clinical trials on aerosol delivery deposition were published in the last decades. In addition, inhaled bronchodilators, mucolytics, antibiotics, and steroids are often administered to ventilated patients in the intensive care units in Taiwan, but they are never studied. Therefore, the aim of this study was to evaluate inhaled bronchodilator and mucolytics (acetylcystine) delivered by a jet nebulizer through a ventilator system to intubated patients.
Peduncular hallucinosis refers to a rare neurophychiatric disorder presenting with vivid visual hallucinations, disturbances of sleep, and oculomotor dysfunction. It is typically caused by mesencephalic lesions. Nonetheless, a few cases have also been reported, in which the same syndrome was associated with thalamic and pontine lesions. We report the case of a 63-year-old male patient presenting to the Emergency Department of our hospital with irritability, gait difficulty, and diplopia of sudden onset two hours ago. Neurological examination revealed dysarthria, right facial palsy, bilateral gaze palsy, dysmetria of his left extremities, left-sided hemihypaethesia and extensory plantar response on the left. Brain computerized tomography (CT) showed a hemorrhagic lesion on the right lateral side of the pons. During his hospitalization at the Department of Neurology, he developed visual hallucinations, confusion, disorientation, insomnia, and strong emotional response. An extensive laboratory screening was performed and showed no abnormal findings. Suspecting peduncular hallucinosis due to the brainstem lesion, treatment with quetiapine and melatonin was administered to the patient and symptoms resolved completely within days. Subsequently, gradual neurological clinical improvement was also noted and two weeks after his admission, a repeated brain CT and a brain magnetic resonance imaging (MRI) showed partial absorption of the brainstem hemorrhage. The patient underwent rehabilitation for two months, showing further clinical improvement, and treatment with quetiapine and melatonin was discontinued without any further episodes being noted. A repeated brain MRI was performed two months after his admission to our hospital and showed no hemorrhage, but a mixed signal intensity core and a hypointense hemosiderin rim at the location of the absorbed hemorrhagic lesion, compatible with pontine carvenoma. Peduncular hallucinosis is most commonly associated with ischemic lesions of the posterior brain blood circulation, but different lesions have been reported, like vasospasm, brain tumors, encephalitis, hemorrhage associated with vascular malformations, such as a carvenoma, as seen in our case, representing a very rare form of peduncular hallucinosis.
Caregivers (MCI or healthy) randomized into this group first complete baseline measures for 16 weeks, consisting of wearing an actigraphy watch, using an under-the-mattress sleep sensor, and, on a weekly basis, completing weight and a health update survey. These baseline measures are optional for PLWD. After 16 weeks of baseline data collection, the primary caregiver continues these measures while walking 3x/week for 16 weeks with their triad. The PLWD optionally completes measures and optionally wears the watch and sleep sensor. Mid- and end-study focus groups during the walking phase evaluate program effectiveness and needed adaptations.
In PKU patients who are responsive to BH4 treatment, blood Phe levels decrease within 24 hours after a single administration of sapropterin dihydrochloride, although maximal effect on Phe level may take up to a month, depending on the patient. A single daily dose of sapropterin dihydrochloride powder for oral solution is adequate to maintain stable blood Phe levels over a 24-hour period. Twelve patients with blood Phe levels ranging from 516 to 986 μmol/L (mean 747 ± 153 micromol/L) were assessed with 24-hour blood Phe level monitoring following a daily morning dose of 10 mg/kg per day. The blood Phe level remained stable during a 24-hour observation period. No substantial increases in blood Phe levels were observed following food intake throughout the 24-hour period.

Sapropterin dihydrochloride dose-response relationship was studied in an open-label, forced titration study at doses of 5 mg/kg per day, then 20 mg/kg per day, and then 10 mg/kg per day (Study 3) [see Clinical Studies (14)]. Individual blood Phe levels were highly variable among patients. The mean blood Phe level observed at the end of each 2-week dosing period decreased as the dose of sapropterin dihydrochloride increased, demonstrating an inverse relationship between the dose of sapropterin dihydrochloride and mean blood Phe levels. 

Cardiac Electrophysiology 

A thorough QTc study was performed in 56 healthy adults. This randomized, placebo and active controlled crossover study was conducted to determine if a single supra-therapeutic (100 mg/kg) dose of sapropterin dihydrochloride, or a single therapeutic dose (20 mg/kg) of sapropterin dihydrochloride had an effect on cardiac repolarization. In this study, sapropterin dihydrochloride was administered after dissolving tablets in water under fed condition. This study demonstrated a dose-dependent shortening of the QT interval. The maximum placebo-subtracted mean change from baseline of the QTc interval was -3.69 and -8.32 ms (lower bound of 90% CI: -5.3 and -10.6 ms) at 20 and 100 mg/kg, respectively.
The invention discloses a monoclonal antibody 5E1 of an anti-Ebola virus glycoprotein GP2 subunit, which has a unique CDR region and specific binding activity with a glycan cap region of an EBOV GP1 subunit. The 5E1 monoclonal antibody and EBOV GP have good combination activity, EC 50 The value was 0.027. mu.g/mL. 5E1 was effective in neutralizing EBOV and BDBV pseudoviruses in vitro, as compared to control antibodies. The neutralizing activity of 5E1 increased with the increase of antibody concentration, and 50% protection was achieved on EBOV and BDBV pseudovirus infected cells at a concentration of 1. mu.g/mL. 5E1 with neutralizing antibody MIL77 bound to GP2 subunit1 and MIL77-2 also did not compete, indicating that 5E1 does not bind to the same epitope as these antibodies. 5E1 has good in vitro neutralizing activity on EBOV and BDBV, can be used as candidate therapeutic drugs for Ebola virus, has different binding epitopes from other neutralizing antibodies, and has the potential of composing cocktail combination therapy with other neutralizing antibodies.
The invention discloses a medicine for treating odontalgia, which is prepared from the following active pharmaceutical ingredients: 20-30g of honeysuckle flower, 20-30g of Paris polyphylla, 20-30g of Fructus Forsythiae, 10-20g of Baikal skullcap root, 10-20g of moutan bark, 10-20g of herba schizonepetae, 5-15g of rhizoma anemarrhenae and 5-15g of Chinese wolfberry. The preparation method comprises the following steps: putting the raw materials on a stir-frying pot, adding water to immerse the raw materials, soaking for 1 hour, boiling with soft fire, continuing decocting for 20-30 minutes, and filtering to remove decoction dregs, thereby obtaining the medicine for treating odontalgia. The medicine for treating odontalgia is preferably taken warmly, and taken orally once a day. The medicine disclosed by the invention can be used for treating odontalgia caused by pulpitis, periodontitis, periodontal disease and the like. The application to 52 patients proves that the medicine for treating odontalgia cures 47 patients, has obvious effect on 2 patients, takes effect on 1 patient, and has no effect on 2 patients. Thus, the effective rate is 90.4%, and the total effective rate is 96.2%.
PURPOSE: A hair treatment agent capable of dying hair and operating at the same time is provided to prevent hair and hands of operators from being damaged. CONSTITUTION: A hair treatment agent is composed of a first material for permanent wave containing a reducing agent and a second material containing an oxidizer. The first permanent wave includes 0.01-10 weight% of thioglycerol and ammonia. The first permanent wave contains a reducing agent and ammonia showing the Fick type diffusion pattern. The hair treatment agent is permanent wave processing agent or curly hair calibration processing agent. The range of the hair treatment is within 9.2-7.5. The hair treatment processes hair. The hair treatment method performs by applying the hair treatment agent after applying the pre-treatment containing reduced alkaline water.
Rituximab will be provided in 500mg/50ml vials; excipients include sodium chloride, tri-sodium citrate dihydrate, polysorbate 80, water for injections. Two vials will be diluted in 500 ml of sodium chloride 0,9% to reach a concentration of 2mg/ml. Rituximab will be administered intravenously in two 1000 mg infusions, with two weeks distance between the first and the second infusion.
Mental health issues have always been the focus of health management. The Lancet Global Commission on Mental Health and Sustainable Development also recommends a broad cross-sectoral approach to mental health issues. With the rapid development of short videos and self-media, watching "Mukbang" is a behavioral way for netizens to alleviate mental health problems such as anxiety and depression. However, watching "Mukbang" can be Internet addictive. At present, there is no research to predict the addictive behavior caused by "Mukbang", and there is no relevant research to explore its addiction mechanism. Although it has been clear that Internet addiction and mental health disorders are significantly related, there is no clear statement on whether there is a common risk factor, a mediating effect, or a causal relationship between the two. The behavior of watching "Mukbang" videos may be in a mediating position between the two. This study will further explore the relationship between the three based on the use and satisfaction theory.
ETHNOPHARMACOLOGICAL RELEVANCE: Astragalus mongholicus Bunge (AMB) is a herb with wide application in traditional Chinese medicine, exerting a wealth of pharmacological effects. AMB has been proven to have an evident therapeutic effect on ischemic cerebrovascular diseases, including cerebral ischemia-reperfusion injury (CIRI). However, the specific mechanism underlying AMB in CIRI remains unclear.
AIM OF THE STUDY: This study aimed to investigate the potential role of AMB in CIRI through a comprehensive approach of network pharmacology and in vivo experimental research.
METHODS: The intersection genes of drugs and diseases were obtained through analysis of the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and Gene Expression Omnibus (GEO) database. The protein-protein interaction (PPI) network was created through the string website. Meanwhile, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was carried out using R studio, and thereafter the key genes were screened. Then, the molecular docking prediction was made between the main active ingredients and target genes, and hub genes with high binding energy were obtained. In addition, molecular dynamic (MD) simulation was used to validate the result of molecular docking. Based on the results of network pharmacology, we used animal experiments to verify the predicted hub genes. First, the rat middle cerebral artery occlusion and reperfusion (MACO/R) model was established and the effective dose of AMB in CIRI was determined by behavioral detection and 2,3,5-Triphenyltetrazolium chloride (TTC) staining. Then the target proteins corresponding to the hub genes were measured by Western blot. Moreover, the level of neuronal death was measured using hematoxylin and eosin (HE) and Nissl staining.
RESULTS: Based on the analysis of the TCMSP database and GEO database, a total of 62 intersection target genes of diseases and drugs were obtained. The KEGG enrichment analysis showed that the therapeutic effect of AMB on CIRI might be realized through the advanced glycation endproduct-the receptor of advanced glycation endproduct (AGE-RAGE) signaling pathway in diabetic complications, nuclear factor kappa-B (NF-κB) signaling pathway and other pathways. Molecular docking results showed that the active ingredients of AMB had good binding potential with hub genes that included Prkcb, Ikbkb, Gsk3b, Fos and Rela. Animal experiments showed that AWE (60 g/kg) could alleviate CIRI by regulating the phosphorylation of PKCβ, IKKβ, GSK3β, c-Fos and NF-κB p65 proteins.
CONCLUSION: AMB exerts multi-target and multi-pathway effects against CIRI, and the underlying mechanism may be related to anti-apoptosis, anti-inflammation, anti-oxidative stress and inhibiting calcium overload.
The invention relates to a method for recovering medicaments or active ingredients from preparations, and from the precursors or wastes thereof, especially in the form of a flat starting material. The invention uses film provided with an adhesive, and a material containing an active ingredient. The starting material is produced with surface areas preferably ranging between 5 and 50 cm2. The starting material comprising a basic active ingredient is introduced into an aqueous extraction liquid having a pH range between 7 and 1, and the starting material comprising an acidic active ingredient is introduced into an aqueous extraction liquid having a pH range between 7 and 13. The extraction liquid is permitted to act until the supporting film detaches from the laminate or until the active ingredient detaches from the supporting film during which a solution containing active ingredients is formed. The extracted medicament or active ingredient is isolated by precipitating it out of the solution containing active ingredients.
the investigators develope two part study. part I: the investigators collect data of 50 patients prospectively programed for general anesthesia and tracheal intubation without predictors of difficult airways. this patients were intubated with cleverscope, the investigators register best cormack-lehane (glottic vision) obtained with Cleverscope and best cormack obtained with direct laryngoscopy. the investigators register intubation succes rate and any complications during its use and after extubation.

part II: after confirm safety and efficacy in patients without difficult airways (part I) the investigators use Cleverscope for the same pourpose on difficult airways patients. collecting same data . the investigators compare cormack-lehane in this patients with Cleverscope and commercial Videolaryngoscope C-MAC.
ABSTRACT This application disclosures medications of a combination immunotherapy for the treatments of cancers and other diseases. The medications of a combination immunotherapy comprise first kind of immunotherapy medication and second kind of immunotherapy medication. The first kind of medication comprises: a check point inhibitor. The second kind medication comprises: at least one of immunization vaccine. The check point inhibitor is selected from a group of: CTLA-4 blockade, PD-1 Inhibitor and PD-L1 inhibitor. The immunization vaccine can be selected from the vaccines available in market or the list of the vaccines that we tested.
The invention relates to therapeutic medicine for a Norwalk virus infection. According to the theoretical analysis of the traditional Chinese medicine, the phenomena of the Norwalk virus infection comprise that the epidemic disease is strong, the heat toxin is internally closed, the damp and the heat are latent, and the spleen and the kidney are in deficiency of yin. The damp is removed by heat clearing and toxicity removing, blood cooling and qi tonifying are carried out, the fire is discharged, and the lockage is opened. The therapeutic medicine is traditional Chinese medicine which can tonify the spleen and the kidney, induce the astringency and cure the diarrhea. The therapeutic medicine for the Norwalk virus infection comprises 10 parts of coptidis rhizome, 7 parts of fresh ginger, 10 parts of radix scutellariae, 15 parts of sanguisorba officinalis, 10 parts of honeysuckle, 10 parts of moutan bark, 15 parts of dried radix rehmanniae, 10 parts of ginseng, 10 parts of fructus schizandrae, 10 parts of rhubarb, 10 parts of jasmines, 10 parts of puerarin, 10 parts of acorus tatarinowii, 10 parts of fructus psoraleae and 10 parts of evodia. The combining therapy is carried out, the correct theoretical scheme for curing the Norwalk virus infection by the traditional Chinese medicine is created, and the obvious curative effect is achieved.
Elderly patients (aged 65 years or older) may have increased sensitivity PERCOCET. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co- administered with other agents that depress respiration. Titrate the dosage of PERCOCET slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see WARNINGS].

These drugs are known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.
The peranal introduction system for bacteria, pref. E. coli and bifidum longum, accommodates them in a casing (1) of water-soluble material, pref. gelatine. They can be live, or freeze-dried and capable of regeneration. The capsule contg. the bacteria can be inserted in the bowel by means of a sleeve, and there released. The sleeve can be cylindrical, contg. a movable inner ejection cylinder, and having a convex forward end, in which here is an opening of cross-section corresponding to that of the capsule. ADVANTAGE - Simple and rapid regeneration of bowel bacteria.
Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 2 mg aflibercept (50 μl of 40 μg/μl solution) IVT on Day 1, Weeks 8, and 16. A sham procedure will also be administered on Day 1.
The present invention provides HIV-derived lentivectors which are multiply modified to create highly safe, efficient, and potent vectors for expressing transgenes for gene therapy. The lentiviral vector comprise various combinations of an inactive central polypurine tract, a stuffer sequence, which may encode drug susceptibility genes, and a mutated hairpin in the 5' leader sequence that substantially abolishes replication. These elements are provided in conjunction with other features of lentiviral vectors, such as a self-inactivating configuration for biosaftey and promoters such as the EF1.alpha. promoter as one example. Additional promoters are also described.  The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element.  These vectors therefore provide useful tools for genetic treatments for inherited and acquired disorders, gene-therapies for cancers and other disease, the creation of industrial and experimental production systems utilizing transformed cells, as well as for the study of basic cellular and genetic processes.
Autoinflammatory diseases, while having a variety of underlying causes, are mediated by dysfunctional innate immune responses. Therefore, standard treatments target innate cytokines or block their receptors. Despite excellent responses in some patients, first-line treatments fail in others, for reasons which remain to be understood. We studied the effects of IL-37, an anti-inflammatory cytokine, on immune cells using multi-omics profiling of 325 healthy adults. Our findings show that IL-37 is associated with inflammation control and generally reduced immune cell activity. Further, genetic variants in IL37 are associated with impaired trained immunity, a memory phenotype of innate immune cells contributing to autoinflammation. To underpin the medical potential of IL-37, an explorative cohort of seven autoinflammatory disorders was built. In vitro stimulation experiments argue for recombinant IL-37 as a potential therapy in IL-6-, and IL-22-driven conditions. Concluding, IL-37 is highlighted as a cytokine with broad anti-inflammatory functions, implicating its potential as therapeutic intervention.